{"id":68994,"date":"2026-03-12T15:22:39","date_gmt":"2026-03-12T15:22:39","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&p=68994"},"modified":"2026-05-21T07:14:11","modified_gmt":"2026-05-21T07:14:11","slug":"cjc-1295-with-dac","status":"publish","type":"product","link":"https:\/\/medsbase.com\/el\/cjc-1295-with-dac\/","title":{"rendered":"CJC-1295 with DAC"},"content":{"rendered":"

<\/p>\n

\n

Quick Answer \u2014 What is CJC-1295 with DAC?<\/h3>\n

CJC-1295 with DAC<\/strong> is a synthetic analog of growth-hormone-releasing hormone (GHRH 1-29) modified with a Drug Affinity Complex (DAC)<\/strong> that binds plasma albumin covalently. The albumin binding extends plasma half-life from ~30 minutes to approximately 7\u00a0days, enabling weekly or twice-weekly research dosing. It is supplied in 2\u00a0mg and 5\u00a0mg lyophilized vials for laboratory research use only.<\/p>\n<\/div>\n

\u0391\u03c5\u03c4\u03cc \u03c0\u03bf\u03c5 \u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03b5\u03c4\u03b5 \u03bc\u03b5 \u03c4\u03b7\u03bd MedsBase:<\/strong> \u0395\u03c1\u03b5\u03c5\u03bd\u03b7\u03c4\u03b9\u03ba\u03ac \u03bb\u03c5\u03bf\u03c6\u03b9\u03bb\u03b9\u03c9\u03bc\u03ad\u03bd\u03b1 \u03c0\u03b5\u03c0\u03c4\u03af\u03b4\u03b9\u03b1 \u00b7 HPLC \u03ba\u03b1\u03b8\u03b1\u03c1\u03cc\u03c4\u03b7\u03c4\u03b1 \u226599% (COA \u03ba\u03b1\u03c4\u03cc\u03c0\u03b9\u03bd \u03b1\u03b9\u03c4\u03ae\u03bc\u03b1\u03c4\u03bf\u03c2) \u00b7 \u0394\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u03c3\u03c4\u03b1\u03b8\u03b5\u03c1\u03ae \u03c3\u03b5 \u03b8\u03b5\u03c1\u03bc\u03bf\u03ba\u03c1\u03b1\u03c3\u03af\u03b1 \u00b7 \u03a0\u03b1\u03b3\u03ba\u03cc\u03c3\u03bc\u03b9\u03b1 \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae \u03c0\u03b5\u03c0\u03c4\u03b9\u03b4\u03af\u03c9\u03bd \u00b7 1,400+ \u03b5\u03c0\u03b1\u03bb\u03b7\u03b8\u03b5\u03c5\u03bc\u03ad\u03bd\u03b1 \u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ad\u03c2 \u03c0\u03b5\u03bb\u03b1\u03c4\u03ce\u03bd<\/a><\/div>\n

\ud83d\udce6 \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/strong><\/a> \u2014 \u03b5\u03ac\u03bd \u03c4\u03bf \u03b4\u03ad\u03bc\u03b1 \u03c3\u03b1\u03c2 \u03b4\u03b5\u03bd \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd, \u03c4\u03bf \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03c5\u03bc\u03b5.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\u03a0\u03c1\u03bf\u03b4\u03b9\u03b1\u03b3\u03c1\u03b1\u03c6\u03ae<\/th>\n\u039b\u03b5\u03c0\u03c4\u03bf\u03bc\u03ad\u03c1\u03b5\u03b9\u03b1<\/th>\n<\/tr>\n<\/thead>\n
\u0391\u03c1\u03b9\u03b8\u03bc\u03cc\u03c2 CAS<\/strong><\/td>\n863288-34-0<\/td>\n<\/tr>\n
\u039c\u03bf\u03c1\u03b9\u03b1\u03ba\u03cc\u03c2 \u03a4\u03cd\u03c0\u03bf\u03c2<\/strong><\/td>\nC165<\/sub>H269<\/sub>N47<\/sub>O46<\/sub><\/td>\n<\/tr>\n
\u039c\u03bf\u03c1\u03b9\u03b1\u03ba\u03cc \u0392\u03ac\u03c1\u03bf\u03c2<\/strong><\/td>\n3647.25 Da<\/td>\n<\/tr>\n
\u0391\u03ba\u03bf\u03bb\u03bf\u03c5\u03b8\u03af\u03b1<\/strong><\/td>\nD-Ala-Tyr-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys-NH2<\/sub> conjugated to maleimidopropionyl-Lys (DAC linker for albumin binding)<\/td>\n<\/tr>\n
\u039c\u03bf\u03c1\u03c6\u03ae<\/strong><\/td>\n\u03a5\u03b1\u03bb\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03b7 \u03c3\u03ba\u03cc\u03bd\u03b7 (\u03ae \u03cc\u03c0\u03c9\u03c2 \u03c0\u03b1\u03c1\u03ad\u03c7\u03b5\u03c4\u03b1\u03b9)<\/td>\n<\/tr>\n
\u039a\u03b1\u03b8\u03b1\u03c1\u03cc\u03c4\u03b7\u03c4\u03b1<\/strong><\/td>\n\u226599% (HPLC \u03b5\u03c0\u03b1\u03bb\u03b7\u03b8\u03b5\u03c5\u03bc\u03ad\u03bd\u03bf, COA \u03ba\u03b1\u03c4\u03cc\u03c0\u03b9\u03bd \u03b1\u03b9\u03c4\u03ae\u03bc\u03b1\u03c4\u03bf\u03c2)<\/td>\n<\/tr>\n
\u0391\u03c0\u03bf\u03b8\u03ae\u03ba\u03b5\u03c5\u03c3\u03b7<\/strong><\/td>\n\u039b\u03c5\u03bf\u03c6\u03b9\u03bb\u03b9\u03c9\u03bc\u03ad\u03bd\u03bf: 2\u20138 \u00b0C (\u03c8\u03c5\u03b3\u03b5\u03af\u03bf) \u03b3\u03b9\u03b1 \u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03b9\u03ba\u03cc \u03b1\u03c0\u03cc\u03b8\u03b5\u03bc\u03b1\u00b7 \u221220 \u00b0C \u03b3\u03b9\u03b1 \u03bc\u03b1\u03ba\u03c1\u03bf\u03c0\u03c1\u03cc\u03b8\u03b5\u03c3\u03bc\u03b7 \u03b1\u03c0\u03bf\u03b8\u03ae\u03ba\u03b5\u03c5\u03c3\u03b7 \u03b1\u03bd\u03bf\u03b9\u03c7\u03c4\u03ce\u03bd \u03c6\u03b9\u03b1\u03bb\u03ce\u03bd. \u0391\u03bd\u03b1\u03c3\u03c5\u03bd\u03c4\u03b5\u03b8\u03b5\u03b9\u03bc\u03ad\u03bd\u03bf: 2\u20138 \u00b0C, \u03c7\u03c1\u03ae\u03c3\u03b7 \u03b5\u03bd\u03c4\u03cc\u03c2 ~30 \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd. \u03a0\u03c1\u03bf\u03c3\u03c4\u03b1\u03c3\u03af\u03b1 \u03b1\u03c0\u03cc \u03c4\u03bf \u03c6\u03c9\u03c2. \u039c\u03b7\u03bd \u03ba\u03b1\u03c4\u03b1\u03c8\u03cd\u03c7\u03b5\u03c4\u03b5-\u03b1\u03c0\u03bf\u03c8\u03cd\u03c7\u03b5\u03c4\u03b5 \u03c4\u03bf \u03b1\u03bd\u03b1\u03c3\u03c5\u03bd\u03c4\u03b5\u03b8\u03b5\u03b9\u03bc\u03ad\u03bd\u03bf \u03b4\u03b9\u03ac\u03bb\u03c5\u03bc\u03b1.<\/td>\n<\/tr>\n
\u0394\u03b9\u03b1\u03bb\u03c5\u03c4\u03cc\u03c4\u03b7\u03c4\u03b1<\/strong><\/td>\n\u0392\u03b1\u03ba\u03c4\u03b7\u03c1\u03b9\u03bf\u03c3\u03c4\u03b1\u03c4\u03b9\u03ba\u03cc \u03bd\u03b5\u03c1\u03cc (\u03c0\u03c1\u03bf\u03c4\u03b5\u03af\u03bd\u03b5\u03c4\u03b1\u03b9) \u03ae \u03c3\u03c4\u03b5\u03b9\u03c1\u03c9\u03bc\u03ad\u03bd\u03bf \u03bd\u03b5\u03c1\u03cc \u03b3\u03b9\u03b1 \u03bc\u03b9\u03ba\u03c1\u03cc\u03c4\u03b5\u03c1\u03b1 \u03c7\u03c1\u03bf\u03bd\u03b9\u03ba\u03ac \u03b4\u03b9\u03b1\u03c3\u03c4\u03ae\u03bc\u03b1\u03c4\u03b1 \u03c7\u03c1\u03ae\u03c3\u03b7\u03c2<\/td>\n<\/tr>\n
\u0395\u03c1\u03b5\u03c5\u03bd\u03b7\u03c4\u03b9\u03ba\u03ae \u03a7\u03c1\u03ae\u03c3\u03b7<\/strong><\/td>\n\u039c\u03cc\u03bd\u03bf \u03b3\u03b9\u03b1 \u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03b7\u03c1\u03b9\u03b1\u03ba\u03ae \u03ad\u03c1\u03b5\u03c5\u03bd\u03b1. \u0394\u03b5\u03bd \u03c0\u03c1\u03bf\u03bf\u03c1\u03af\u03b6\u03b5\u03c4\u03b1\u03b9 \u03b3\u03b9\u03b1 \u03b4\u03b9\u03b1\u03b3\u03bd\u03c9\u03c3\u03c4\u03b9\u03ba\u03ae \u03ae \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03c5\u03c4\u03b9\u03ba\u03ae \u03c7\u03c1\u03ae\u03c3\u03b7 \u03c3\u03b5 \u03b1\u03bd\u03b8\u03c1\u03ce\u03c0\u03bf\u03c5\u03c2 \u03ae \u03b6\u03ce\u03b1.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/p>\n

What Is CJC-1295 with DAC?<\/h2>\n

CJC-1295<\/strong> is a synthetic 30-amino-acid analog of growth-hormone-releasing hormone (GHRH), specifically a modified form of the biologically-active GHRH (1-29) fragment. The “with DAC<\/strong>” suffix refers to a proprietary Drug Affinity Complex (DAC)<\/strong> \u2014 a maleimidopropionic acid residue attached to lysine-30 \u2014 which forms a covalent bond with serum albumin cysteine-34 in vivo<\/em>.<\/p>\n

That albumin tether is the key innovation. Native GHRH has a plasma half-life measured in minutes (rapid DPP-IV degradation); CJC-1295 with DAC circulates bound to albumin for approximately 7 \u03b7\u03bc\u03ad\u03c1\u03b5\u03c2<\/strong>, enabling weekly or twice-weekly research dosing while sustaining GH\/IGF-1 elevation between injections. This is a fundamentally different pharmacokinetic profile from the “without DAC” version (sometimes called Mod GRF 1-29) which retains native GHRH’s short half-life. Developed by ConjuChem, CJC-1295 is for laboratory research use only<\/strong> and is not intended for human or veterinary diagnosis or therapy. For mechanism, research context, and stacking protocols, see our Ipamorelin & CJC-1295 research guide<\/a>.<\/p>\n

Mechanism of Action \u2014 Extended-Release GHRH Agonism<\/h2>\n

CJC-1295 with DAC acts through two sequential mechanisms:<\/p>\n